Corcept Therapeutics vs Pacira Biosciences
Corcept Therapeutics and Pacira Biosciences are similar in size: $761m and $726m of revenue in their latest fiscal years. Corcept Therapeutics grew faster (12.8% against 3.6%). Corcept Therapeutics kept more of each dollar of sales as profit: a net margin of 13.1% against 1.0%. Corcept Therapeutics carries less debt relative to equity (0.0% against 53.7%).
| Latest fiscal year | Corcept TherapeuticsCORT, 2025 | Pacira BiosciencesPCRX, 2025 |
|---|---|---|
| Revenue | $761m | $726m |
| Revenue growth | 12.8% | 3.6% |
| Net income | $99.7m | $7.0m |
| Operating margin | 5.9% | 2.6% |
| Net margin | 13.1% | 1.0% |
| Return on equity | 15.0% | 1.0% |
| Free cash flow | $142m | $137m |
| Cash | $120m | $159m |
| Total debt | $0 | $372m |
| Debt to equity | 0.0% | 53.7% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $173m | $148m |
| Employees | 730 | 829 |
| Market value | $8.82bn | $1.45bn |
| Price vs our value range | Above our value range | Below our value range |
| Moat score | 75 (Strong) | 55 (Moderate) |
| Insider trades, 12 months | 2 buys, 111 sales | 0 buys, 17 sales |